Merck says no safety concerns observed in molnupiravir phase-3 trial, shared relevant data with DCGI

The company said it has provided relevant information as requested to help the DCGI determine the most appropriate use of molnupiravir in India.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/34ofngx